Novartis Intrinsic Value
Novartis intrinsic value. Novartis (NOVARTIND) median intrinsic value is ₹871.20 from 10 valuation models (range ₹590–₹1363), vs current price ₹1967.80 — -55.7% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit NOVARTIND screener.
NOVARTIND Valuation Methods Summary — DCF, Graham Number & P/E
Novartis intrinsic value across 10 models vs current price ₹1967.80 — upside/downside and value range per method. Read Novartis dividend payments for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹871.20 | ₹696.96 - ₹1045.44 | -55.7% | EPS: ₹39.60, Sector P/E: 22x |
| Book Value Method | asset | ₹1363.33 | ₹1227.00 - ₹1499.66 | -30.7% | Book Value/Share: ₹681.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹680.00 | ₹612.00 - ₹748.00 | -65.4% | Revenue/Share: ₹340.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1158.33 | ₹1042.50 - ₹1274.16 | -41.1% | EBITDA: ₹139.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹787.12 | ₹629.70 - ₹944.54 | -60.0% | CF Growth: 4.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹590.34 | ₹531.31 - ₹649.37 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹590.34 | ₹531.31 - ₹649.37 | -70.0% | Revenue Growth: -1.7%, Adj P/E: 14.9x |
| ROE Based Valuation | profitability | ₹983.90 | ₹885.51 - ₹1082.29 | -50.0% | ROE: 12.0%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹779.34 | ₹701.41 - ₹857.27 | -60.4% | EPS: ₹39.60, BVPS: ₹681.67 |
| Dividend Yield Method | dividend | ₹1000.00 | ₹900.00 - ₹1100.00 | -49.2% | DPS: ₹25.00, Target Yield: 2.5% |
NOVARTIND Intrinsic Value vs Market Price — All Valuation Models
Novartis fair value range ₹590–₹1363 vs current market price ₹1967.80 across 10 valuation models. Compare with Novartis value estimation to assess whether the stock is under or overvalued.
NOVARTIND Intrinsic Value Analysis — Undervalued or Overvalued?
Novartis median intrinsic value ₹871.20, current price ₹1967.80 — Trading Above Calculated Value by 55.7%, margin of safety -100.0%.
What is the intrinsic value of NOVARTIND?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Novartis (NOVARTIND) is ₹871.20 (median value). With the current market price of ₹1967.80, this represents a -55.7% variance from our estimated fair value.
The valuation range spans from ₹590.34 to ₹1363.33, indicating ₹590.34 - ₹1363.33.
Is NOVARTIND undervalued or overvalued?
Based on our multi-method analysis, Novartis (NOVARTIND) appears to be trading above calculated value by approximately 55.7%.
NOVARTIND Financial Health — Key Ratios vs Industry Benchmarks
Novartis financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 48.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 12.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.42x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
NOVARTIND Cash Flow Quality — Operating & Free Cash Flow
Novartis operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹47 Cr | ₹47 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹75 Cr | ₹74 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹113 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹45 Cr | ₹-32 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹39 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |